Get the Stockscreener App
24.16
2.24%
0.53
After Hours:
24.16
Evommune Inc stock is traded at $24.16, with a volume of 801.44K.
It is up +2.24% in the last 24 hours and up +1.85% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$23.63
Open:
$23.83
24h Volume:
801.44K
Relative Volume:
1.35
Market Cap:
$870.20M
Revenue:
$13.00M
Net Income/Loss:
$-68.87M
P/E Ratio:
-10.85
EPS:
-2.2276
Net Cash Flow:
$-76.68M
1W Performance:
-5.55%
1M Performance:
+1.85%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.51
$24.90
1-Week Range:
$23.10
$25.52
52-Week Range:
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
24.16 | 851.11M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-26 | Resumed | Oppenheimer | Outperform |
| Jan-22-26 | Initiated | Oppenheimer | Outperform |
| Jan-08-26 | Initiated | Raymond James | Strong Buy |
| Jan-06-26 | Initiated | H.C. Wainwright | Buy |
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
View All
Evommune Inc Stock (EVMN) Latest News
Certain Rights of Evommune, Inc. are subject to a Lock-Up Agreement Ending on 5-MAY-2026. - marketscreener.com
Wall Street Zen Downgrades Evommune (NYSE:EVMN) to Sell - MarketBeat
Stifel Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Stifel Nicolaus - MarketBeat
Stifel initiated coverage on Evommune with a new price target - Quantisnow
Stifel Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $54 - Moomoo
Evommune and BillionToOne climb on trading debut - MSN
Evommune surges on mid-stage trial win for eczema therapy - MSN
Evommune, Inc. (NYSE:EVMN) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Evommune, Inc.'s (NYSE:EVMN) Lock-Up Period To Expire on May 5th - MarketBeat
[EFFECT] Evommune, Inc. SEC Filing - Stock Titan
Evommune’s EVO756 Phase 2b Trial: An Emerging Catalyst in Atopic Dermatitis - TipRanks
Evommune (NYSE: EVMN) registers 4.49M shares for resale by investors - Stock Titan
EVMN Options Chain — NYSE:EVMN - TradingView
Oppenheimer Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Evommune, Inc. Common Stock (NY: EVMN - FinancialContent
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
Evommune Shelf Registration Raises Dilution Questions After Strong Share Gains - Sahm
EVMN Evommune reports wider Q4 2025 loss than analyst projections, shares dip modestly on soft quarterly earnings.Market Hype Signals - UBND thành phố Hải Phòng
Evommune (EVMN) details 2026 director votes and CEO pay in proxy - Stock Titan
Why is Evommune (EVMN) stock going up today (Institutional Selling) 2026-04-20AI Signals - Cổng thông tin điện tử Tỉnh Sơn La
Evommune (EVMN) Chief Scientific Officer awarded 69,315 stock options at $26.77 - Stock Titan
Evommune (EVMN) grants 73,892 stock options to development chief - Stock Titan
[Form 4] Evommune, Inc. Insider Trading Activity - Stock Titan
Evommune (EVMN) grants CFO 98,946 options at $26.77 strike - Stock Titan
Evommune (EVMN) grants 115,279 stock options to chief legal officer - Stock Titan
Evommune (EVMN) CEO Luis C. Pena receives 291,420 stock option grant - Stock Titan
Evommune Incprospectus filed for resale of up to 4.5 million shares of Evommune common stock by selling stockholdersSEC filing - marketscreener.com
Evommune (NYSE: EVMN) investors file to resell 4.49M previously issued shares - Stock Titan
Evommune stock price target reaffirmed at $50 by H.C. Wainwright - Investing.com South Africa
H.C. Wainwright Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Velan Capital Investment Management LP's Evommune Inc(EVMN) Holding History - GuruFocus
Evommune Makes Case For MRGPRX2 Inhibition in Migraine - Citeline News & Insights
MRGPRX2: A Novel Target in Migraine Treatment – EVO756’s Potential in Migraine Prophylaxis Explained - Minichart
William Blair Maintains Evommune(EVMN.US) With Buy Rating - Moomoo
Evommune: Differentiated MRGPRX2 Strategy and Upcoming EVO756 Phase IIb Readout Support Buy Rating - TipRanks
Evommune Spotlights EVO756 as Novel Preventive Migraine Therapy - TipRanks
Evommune (EVMN) advances oral MRGPRX2 migraine drug EVO756 toward Phase 2b - Stock Titan
RBC Capital Reaffirms Their Buy Rating on Evommune, Inc. (EVMN) - The Globe and Mail
Evommune (NYSE:EVMN) Stock Price Down 7.2%Here's Why - MarketBeat
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says - marketscreener.com
Today's Analyst Rating Update for EVMN: Maintained at Outperform - GuruFocus
Evommune (NYSE:EVMN) Earns Outperform Rating from Royal Bank Of Canada - MarketBeat
RBC Capital Maintains Evommune(EVMN.US) With Buy Rating, Maintains Target Price $48 - Moomoo
Evommune (EVMN) Institutional Ownership 2026 - MarketBeat
Evommune (NYSE:EVMN) Advances Within Biotechnology Research And Development - Kalkine Media
Oppenheimer Initiates Evommune(EVMN.US) With Buy Rating, Announces Target Price $50 - Moomoo
Evommune (NYSE:EVMN) Shares Up 4.7%Here's What Happened - MarketBeat
Oppenheimer Initiates Coverage on Evommune (NYSE:EVMN) - MarketBeat
Evommune bucked biotech IPO drought and is focused on the long game - Pharma Voice
Oppenheimer initiates Evommune stock rating at Outperform, $50 target By Investing.com - Investing.com Australia
Evommune Inc Stock (EVMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):